FREQUENCY OF RESISTANCE TO SYSTEMICALLY ADMINISTERED MEGLUMINE ANTIMONIATE (GLUCANTIME) IN PATIENTS WITH ACUTE CUTANEOUS LEISHMANIASIS: A CROSS-SECTIONAL STUDY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NILFROUSHZADEH M.A.; ANSARI N.; DERAKHSHAN R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Dermatology Year:2006 | Volume:8 | Issue:6 (34) Page(s): 457-461

Download Full-Text

Persian Verion

View:

1,300

Download:

Cites:

Information Journal Paper

Title

FREQUENCY OF RESISTANCE TO SYSTEMICALLY ADMINISTERED MEGLUMINE ANTIMONIATE (GLUCANTIME) IN PATIENTS WITH ACUTE CUTANEOUS LEISHMANIASIS: A CROSS-SECTIONAL STUDY

Author(s)

NILFROUSHZADEH M.A. | ANSARI N. | DERAKHSHAN R. | Issue Writer Certificate

Keywords

CUTANEOUS LEISHMANIASISQ4

DRUG RESISTANCEQ2

MEGLUMINE ANTIMONIATEQ3

IRANQ3

Abstract

Background and aim: Pentavalent antimony compounds are the first line treatment for CUTANEOUS LEISHMANIASIS. Clinical resistance to pentavalent antimony in the form of MEGLUMINE ANTIMONIATE (Glucantime) has been recognized as a problem in leishmaniasis. Herein, clinical response to Glucantime was studied in patients suffered from CUTANEOUS LEISHMANIASIS.Materials and Methods: In a cross-sectional study 370 patients with CUTANEOUS LEISHMANIASIS were treated with systemic Glucantime, 50 mg/kg/day, for 2 to 3 weeks. They were visited weekly for 3 weeks and also followed up for 3 months after treatment was completed. The clinical and parasitological response to this treatment was evaluated, and classified into partial and complete response and failure to treatment.Results: Two hundred forty-seven men and 123 women were followed up. The mean age was 36.7±16 years. There were 64.1% partial response after 2 weeks and 73% partial response at the third week of treatment. 11.6% of lesions were not cured after 3 weeks of treatment and 8.1% were not still cured 12 weeks thereafter.Conclusion: Clinical resistance to Glucantime is an important problem. The mechanisms of resistance and using drug combinations are needed to be considered.

Cites

No record.

References

بررسی اثرات درمانی و عوارض جانبی گلوکانتیم در بیماران سالک

Cite

APA: Copy

NILFROUSHZADEH, M.A., ANSARI, N., & DERAKHSHAN, R.. (2006). FREQUENCY OF RESISTANCE TO SYSTEMICALLY ADMINISTERED MEGLUMINE ANTIMONIATE (GLUCANTIME) IN PATIENTS WITH ACUTE CUTANEOUS LEISHMANIASIS: A CROSS-SECTIONAL STUDY. IRANIAN JOURNAL OF DERMATOLOGY, 8(6 (34)), 457-461. SID. https://sid.ir/paper/57737/en

Vancouver: Copy

NILFROUSHZADEH M.A., ANSARI N., DERAKHSHAN R.. FREQUENCY OF RESISTANCE TO SYSTEMICALLY ADMINISTERED MEGLUMINE ANTIMONIATE (GLUCANTIME) IN PATIENTS WITH ACUTE CUTANEOUS LEISHMANIASIS: A CROSS-SECTIONAL STUDY. IRANIAN JOURNAL OF DERMATOLOGY[Internet]. 2006;8(6 (34)):457-461. Available from: https://sid.ir/paper/57737/en

IEEE: Copy

M.A. NILFROUSHZADEH, N. ANSARI, and R. DERAKHSHAN, “FREQUENCY OF RESISTANCE TO SYSTEMICALLY ADMINISTERED MEGLUMINE ANTIMONIATE (GLUCANTIME) IN PATIENTS WITH ACUTE CUTANEOUS LEISHMANIASIS: A CROSS-SECTIONAL STUDY,” IRANIAN JOURNAL OF DERMATOLOGY, vol. 8, no. 6 (34), pp. 457–461, 2006, [Online]. Available: https://sid.ir/paper/57737/en

Related Journal Papers